KR102502598B1 - A composition for improving, preventing and treating of inflammatory or atopic dermatitis comprising Sargassum thunbergii extract - Google Patents

Abstract

The present invention relates to a composition for the improvement, prevention or treatment of atopic dermatitis or allergic dermatitis, comprising an extract of wormworm as an active ingredient, and more particularly, the extract of wormworm of the present invention is induced by the expression of MDC or TARC. While inhibiting atopic dermatitis or allergic dermatitis, it does not exhibit cytotoxicity in weakened cells where inflammation is induced, so it has excellent stability, and it is obtained from natural products and has no side effects on the human body and has excellent stability, so improvement of atopic dermatitis or allergic dermatitis using it , It can be applied to a preventive or therapeutic composition.

Description

A composition for improving, preventing, and treating inflammatory or atopic dermatitis comprising Sargassum thunbergii extract}

The present invention relates to a composition for improving, preventing or treating atopic dermatitis or allergic dermatitis, comprising an extract of streptococci as an active ingredient.

Allergy is a systemic or local disorder of a living body based on an immune response. Allergies appearing in the human body are classified into types I, II, III, and IV depending on the immune mechanism. Among them, type I allergy, which belongs to the immediate hypersensitivity reaction, occupies an important part in clinical practice, and atopic dermatitis, allergic rhinitis, bronchial asthma, hay fever, and hay fever belong to this category.

In particular, Atopic Dermatitis (AD) is an inflammatory skin disease accompanied by itching, which is chronic and usually begins in infancy. Atopic dermatitis has constant itching as its main symptom, and has the characteristic of repeating recovery and deterioration without a specific reason. The cause of atopic dermatitis has not yet been clearly identified despite numerous recent studies, and various treatments are being developed, but interest in natural materials that can reduce skin irritation is increasing.

On the other hand, Sargassum thunbergii is a pseudoperennial that is easily observed in rock bedrock and tide pools in the middle and lower intertidal zones of Korea, Japan and China, and in which the fronds are shed in the fall and new fronds are produced in the winter in the surviving adherens. ) is a seaweed. Earthworms have long been used as insect repellents, food, or compost, and play an important role in the marine ecosystem as basic producers, food, hiding places, and spawning grounds for animals. In addition, with the recent increase in interest in marine natural products, an anticancer substance that inhibits the growth of cancer cells has been discovered in the extract of larvae, making it one of the seaweeds with high added value in the future.

However, there has been no case of applying atopic dermatitis or allergic dermatitis as a composition for improving, preventing, or treating atopic dermatitis using earthworms.

Korean Patent Registration No. 10-1794114

In order to solve the above problems, an object of the present invention is to provide a cosmetic composition for preventing or alleviating atopic dermatitis or allergic dermatitis, comprising an extract of streptococci as an active ingredient.

In addition, an object of the present invention is to provide a pharmaceutical composition for preventing or treating atopic dermatitis or allergic dermatitis, comprising an extract of streptococci as an active ingredient.

In addition, an object of the present invention is to provide a composition for external application for skin for preventing or treating atopic dermatitis or allergic dermatitis, comprising an extract of streptococci as an active ingredient.

In addition, an object of the present invention is to provide a quasi-drug composition for preventing or improving atopic dermatitis or allergic dermatitis, comprising an extract of streptomycin as an active ingredient.

In addition, an object of the present invention is to provide a health functional food composition for preventing or improving atopic dermatitis or allergic dermatitis, comprising an extract of streptococci as an active ingredient.

In the present specification, "extract" refers to an extract obtained by extraction treatment, a diluted solution or concentrate of the extract, a dried product obtained by drying the extract, a crude or purified product of the extract, or a mixture thereof, etc. It includes extracts of all possible formulations. The extract of the present invention may be extracted from natural, hybrid or mutant plants of each corresponding plant, and may also be extracted from plant tissue culture.

In the present specification, "comprising as an active ingredient" means including an amount sufficient to achieve the efficacy or activity of improving, treating or preventing inflammation or atopic dermatitis of the extract of Pythia japonica of the present invention.

In the present specification, "prevention" may mean any action that suppresses, delays, or alleviates itching by administering the composition according to the present invention to a subject.

As used herein, "treatment" may refer to any action to improve or benefit from itching symptoms by administering the composition according to the present invention to a subject suspected of having inflammation or atopic dermatitis.

The present invention relates to a composition for improving, preventing or treating atopic dermatitis or allergic dermatitis, comprising an extract of streptococci as an active ingredient.

Atopic dermatitis or allergic dermatitis is an inflammatory skin disease accompanied by itching, and keratinocytes (HaCaT) contain high concentrations of inflammation-inducing cytokines such as TNF-α and IFN-γ. These inflammation-inducing cytokines are TARC (thymus and activation). -regulated chemokine) and MDC production. As a result, the concentration of cytokines has been found to be closely related to the symptoms of atopic dermatitis or allergic dermatitis accompanied by itching, and TARC and MDC are reliable biomarkers that best reflect these diseases.

Accordingly, in the present invention, the expression of TARC and MDC, which are biomarkers representing inflammatory diseases of atopic dermatitis or allergic dermatitis, such as TARC and MDC, is inhibited, and cytotoxicity is inhibited in cells treated with TNF-α and IFN-γ, which are inflammation inducers. As a result of efforts to discover new substances that are not shown, it was confirmed that the extract of the earthworm, especially the extract extracted with 60 to 80% by weight of ethanol, can effectively inhibit atopic dermatitis or allergic dermatitis. In particular, it was found that the streptomycin extract of the present invention has an excellent anti-atopic effect, including an aldehyde-based compound, and has no side effects on the human body and excellent stability by using a natural material having such an anti-atopic effect.

Specifically, the present invention provides a cosmetic composition for preventing or improving atopic dermatitis or allergic dermatitis, comprising Sargassum thunbergii extract as an active ingredient.

The locust extract may be an extract extracted with one or more solvents selected from the group consisting of water, methanol, ethanol, butanol, propanol, ethyl acetate, acetone, nucleic acid, and dichloromethane. Preferably, it may be one or more solvents from the group consisting of methanol, ethanol and butanol, and most preferably ethanol.

In particular, when ethanol is used as a solvent, the streptomycin extract can be extracted with 60 to 80% by weight, preferably 65 to 75% by weight, most preferably 70% by weight of ethanol. At this time, if the content of the ethanol is less than 60% by weight, the active ingredient may not be sufficiently extracted from the extract of the landworm, and conversely, if it exceeds 80% by weight, further improved extraction yield cannot be expected.

The extraction method of the locust extract is not particularly limited, and can be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method include solvent extraction, hot water extraction, ultrasonic extraction, filtration, reflux extraction, and the like, which may be performed alone or in combination of two or more methods. Preferably, it may be performed by solvent extraction.

The solvent extraction method can be extracted at an extraction temperature of 10 to 80 ° C, preferably 15 to 60 ° C, for an extraction time of 2 hours to 10 days, preferably 12 hours to 5 days, including the drying and lysate It may include a process of obtaining a liquid crude extract by extracting 1 to 5 times in succession.

The locust extract is at a concentration of 5 to 250 μg/ml, preferably 10 to 100 μg/ml, more preferably 50 to 100 μg/ml, and most preferably 100 μg/ml, based on the total content of the cosmetic composition. can be included At this time, if the content of the tripod extract is less than 5 μg/ml, the cell viability is excellent, but the content of the tripod extract is relatively low, so the effect of effectively suppressing atopic dermatitis or allergic dermatitis may be insignificant. On the contrary, if it exceeds 250 μg/ml, cell viability may rapidly decrease due to strong cytotoxicity.

The locust extract may contain an aldehyde-based compound as an active ingredient.

The cosmetic composition does not exhibit cytotoxicity in cells such as HaCaT induced by TNF-α and IFN-γ, which are inflammatory cytokines, by including an extract of streptomycin as an active ingredient, and is resistant to atopic dermatitis or atopic dermatitis by TNF-α and IFN-γ. It suppresses and inhibits the expression of biomarkers of TARC and MDC in allergic dermatitis-induced cells and has a remarkable effect on preventing or improving atopic dermatitis or allergic dermatitis. The atopic dermatitis or allergic dermatitis may be induced by expression of MDC or TARC.

Ingredients included in the cosmetic composition include ingredients commonly used in cosmetic compositions in addition to the stratus extract as an active ingredient, for example, antioxidants, stabilizers, solubilizers, vitamins, and conventional adjuvants and carriers such as flavoring agents. may further include.

The cosmetic composition is a suspension, emulsion, paste, gel, cream, atopic soap, cleansing foam, cleansing cream, cleansing water, bath agent, skin softener, skin toner, lotion, cream, essence, astringent, emulsion, gel, lipstick, It may be any one formulation selected from the group consisting of a spray, shampoo, rinse, treatment, body cleanser, pack, massage, face powder, compact, foundation, two-way cake, and makeup base.

When the formulation of the cosmetic composition is a paste, cream or gel, vegetable oil, wax, starch, cellulose, silicone, bentonite, silica, zinc oxide, etc. may be further included as a carrier component, and when the formulation is a powder, lactose as a carrier component , silica, aluminum hydroxide, calcium silicate, etc. may further contain powder. When the formulation of the cosmetic composition is an emulsion, it may further include a solvent, a solubilizing agent or an emulsifying agent as a carrier component, such as water, ethanol, glycerin, ethyl carbonate, ethyl acetate, propylene glycol, butylene glycol , 1,2-hexanediol, glycerol aliphatic esters, and sorbitan fatty acid esters.

When the formulation of the cosmetic composition is a suspension, as a carrier component, a liquid diluent such as water, ethanol, or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester , microcrystalline cellulose, aluminum metahydroxide, bentonite, agar and the like may be further included.

On the other hand, the present invention provides a pharmaceutical composition for preventing or treating atopic dermatitis or allergic dermatitis, comprising Sargassum thunbergii extract as an active ingredient.

The locust extract may be extracted with 60 to 80% by weight, preferably 65 to 75% by weight, most preferably 70% by weight of ethanol.

The concentration of the locust extract is 5 to 250 μg/ml, preferably 10 to 100 μg/ml, more preferably 50 to 100 μg/ml, and most preferably 100 μg/ml, based on the total content of the pharmaceutical composition. can be included as

A suitable dosage of the pharmaceutical composition varies depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate and reaction sensitivity, usually A skilled practitioner can readily determine and prescribe dosages effective for the desired treatment or prophylaxis. According to a preferred embodiment, the daily dose of the pharmaceutical composition is 0.001 to 10 g/kg.

The pharmaceutical composition can be administered orally or parenterally, and in the case of parenteral administration, it can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc., preferably oral administration.

The pharmaceutical composition further comprises at least one selected from the group consisting of pharmaceutically acceptable carriers, excipients and diluents according to a method that can be easily performed by those skilled in the art. It may be prepared in unit dose form by formulation including, or prepared by inserting into a multi-dose container. At this time, the dosage form may be any one selected from the group consisting of granules, powders, tablets, coatings, capsules, solutions, syrups, juices, suspensions, emulsions, drops and injections.

The pharmaceutical composition includes medicines for human use and for animals. Specifically, the extract of Pygonia can be used in the manufacture of various veterinary medicines. At this time, the animal drug can be used as an animal drug or supplement that can efficiently treat and prevent atopic dermatitis disease in animals, an auxiliary treatment agent that can enhance therapeutic efficacy, and a feed additive.

In addition, the present invention provides a composition for external application for skin for preventing or treating atopic dermatitis or allergic dermatitis, comprising Sargassum thunbergii extract as an active ingredient.

The locust extract may be extracted with 60 to 80% by weight, preferably 65 to 75% by weight, most preferably 70% by weight of ethanol.

The concentration of the streptococcus extract is 5 to 250 μg/ml, preferably 10 to 100 μg/ml, more preferably 50 to 100 μg/ml, and most preferably 100 μg/ml, based on the total content of the composition for external application for skin. can be included as

The composition for external application for skin may be any one formulation selected from the group consisting of creams, gels, ointments, emulsions, suspensions, sprays, and transdermal delivery patches.

In addition, the present invention provides a quasi-drug composition for preventing or improving atopic dermatitis or allergic dermatitis, comprising Sargassum thunbergii extract as an active ingredient.

The locust extract may be extracted with 60 to 80% by weight, preferably 65 to 75% by weight, most preferably 70% by weight of ethanol.

The locust extract is at a concentration of 5 to 250 μg/ml, preferably 10 to 100 μg/ml, more preferably 50 to 100 μg/ml, and most preferably 100 μg/ml, based on the total content of the quasi-drug composition. can be included

The quasi-drug composition may further include a pharmaceutically acceptable carrier, excipient or diluent as needed in addition to the above components. The pharmaceutically acceptable carrier, excipient or diluent is not limited as long as the effect of the present invention is not impaired, and examples thereof include fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, aromatics, preservatives, and the like. can include

The quasi-drug composition may include, but is not limited to, disinfectant cleanser, shower foam, ointment, wet tissue, coating agent, etc., and the formulation method, capacity, usage method, and components of the quasi-drug are conventional techniques known in the art. can be appropriately selected from.

In addition, the present invention provides a health functional food composition for preventing or improving atopic dermatitis or allergic dermatitis, comprising Sargassum thunbergii extract as an active ingredient.

The locust extract may be extracted with 60 to 80% by weight, preferably 65 to 75% by weight, most preferably 70% by weight of ethanol.

The locust extract is 5 to 250 μg/ml, preferably 10 to 100 μg/ml, more preferably 50 to 100 μg/ml, and most preferably 100 μg/ml, based on the total content of the health functional food composition. concentration may be included.

The health functional food composition is any one formulation selected from the group consisting of capsules, tablets, powders, granules, liquids, pills, flakes, pastes, syrups, gels, jellies, and bars, and when ingested, certain effects on health However, unlike general drugs, it has the advantage of not having side effects that can occur when taking drugs for a long time using food as a raw material.

The health functional food composition may include ingredients commonly added during food preparation, as well as dandelion extract as an active ingredient, and may include, for example, proteins, carbohydrates, fats, nutrients, seasonings, and flavoring agents. can Examples of the aforementioned carbohydrates include monosaccharides such as glucose, fructose, and the like; disaccharides such as maltose, sucrose, oligosaccharides and the like; and polysaccharides such as conventional sugars such as dextrins and cyclodextrins and sugar alcohols such as xylitol, sorbitol and erythritol.

As the flavoring agent, natural flavoring agents such as thaumatin, stevia extract, and synthetic flavoring agents may be used. In this case, the stevia extract may be rebaudioside A, glycyrrhizin, and the like, and the synthetic flavoring agent may be saccharin, aspartame, and the like. For example, when the health functional food composition is prepared as a drink or beverage, citric acid, high fructose corn syrup, sugar, glucose, acetic acid, malic acid, fruit juice, various plant extracts, etc. may be further included in addition to the dandelion extract of the present invention. .

The earthworm extract according to the present invention inhibits atopic dermatitis or allergic dermatitis induced by the expression of MDC or TARC, but does not exhibit cytotoxicity in weakened cells induced by inflammation, and thus has excellent stability, thereby preventing atopic dermatitis or allergic dermatitis. It can be used as a composition for improvement, prevention or treatment.

In addition, since the earthworm extract according to the present invention is obtained from a natural product and has no side effects on the human body and has excellent stability, it can be applied to a health functional food composition for preventing or improving atopic dermatitis or allergic dermatitis.

The effects of the present invention are not limited to the effects mentioned above. It should be understood that the effects of the present invention include all effects that can be inferred from the following description.

1 is a graph showing the results of evaluating the viability of HaCaT cells prepared in Example 1 of the present invention treated with 70% by weight ethanol extract.
Figure 2 shows the mRNA expression levels of MDC (a) and TARC (b) in HaCaT cells induced with IFN-γ and TNF-α cytokines, according to the treatment of 70 wt% ethanol extract of striatum prepared in Example 1 of the present invention. This is a graph comparing
Figure 3 shows the protein expression levels of MDC (a) and TARC (b) in HaCaT cells induced with IFN-γ and TNF-α cytokines, according to the treatment of 70 wt% ethanol extract of striatum prepared in Example 1 of the present invention. This is a graph comparing
FIG. 4 shows the MAPKs and SAAT1 pathways of HaCaT cells induced with IFN-γ and TNF-α cytokines in the worm prepared in Example 1 of the present invention after treatment with 70 wt% ethanol extract.
5 shows the results of HPLC analysis of the 70% by weight ethanol extract of the worm prepared in Example 1 of the present invention.

Hereinafter, the present invention will be described in more detail based on examples, but the present invention is not limited by the following examples.

Example 1: Preparation of streptococcus extract

70% by weight of ethanol was added to Sargassum thunbergii , extracted at room temperature for 24 hours (What man filter paper), filtered through a 185 mm filter, concentrated at 45 ° C, and solid content was obtained. Then, 200 mg of the concentrated solid content was added to 1 ml of DMSO and then diluted to prepare a 70% by weight ethanol extract of the streptococcus.

Experimental Example 1: Analysis of cell viability according to streptococcus extract

Cytotoxicity was measured to examine the effect of the striatum prepared in Example 1 on the survival rate of HaCaT keratinocytes induced by IFN-γ and TNF-α cytokines with respect to 70 wt% ethanol extract. Specifically, human-derived keratinocytes, the HaCaT cell line, were cultured under 37 °C and 5% CO ₂ conditions, each containing 1% penicillin-streptomycin and 10% fetal bovine serum in DMEM (Dulbecco's Modified Eagle's Medium) culture medium (Gibco BRL, USA). The HaCaT cell line cultured under the above conditions was dispensed into a 96-well plate or a 10 ml culture dish at an amount of 1 × 10 ⁵ strains (cell)/ml and cultured for 24 hours, then the medium was removed and a new medium was added. The control group did not contain 70% by weight ethanol extract of the worm, an inflammatory factor, but only the medium was added, and the experimental group was treated with 70% ethanol extract (0, 10, 50, 0, 10, 50, 100, 500 μg/ml) were added. After culturing the control and experimental groups for 24 hours, cell viability was measured.

In order to compare the cell viability according to the concentration of the 70% by weight ethanol extract of the worm, after recovering each cell prepared in Experimental Example 1, MTT (3-(4,5-dimethylthiazol-2-yl)-2 ,5-diphenyl tetrazolium) solution (0.05 mg/ml concentration) was added, incubated in a cell incubator for 4 hours to induce a reduction reaction, then the MTT solution was removed and DMSO was added to completely form formazan crystals. dissolved 200 μl of this was added to each well and the absorbance at 570 nm was measured using a microplate reader. The results are shown in Figure 1.

1 is a graph showing the results of evaluating the viability of HaCaT cells prepared in Example 1 treated with 70% by weight ethanol extract. Referring to FIG. 1, when the worms were treated with 70% by weight ethanol extract from 10 μg/ml to 500 μg/ml, it was confirmed that the highest concentration showing a cell viability of 80% or more was up to 100 μg/ml.

Experimental Example 2: Atopy-related gene expression level analysis

RT-PCR and ELISA targeting TARC and MDC, which are anti-atopic biomarkers among cytokines, were sequentially analyzed using 70% by weight ethanol extract of the streptomyces prepared in Example 1. The evaluation method measured TARC and MDC chemokine expression levels by concentration of 70% by weight ethanol extract from streptomyces when HaCaT cells were treated with stimulating (TNF-α, IFN-γ) cytokines through ELISA, Through this, the anti-atopic effect at the protein level was confirmed. The results are shown in Figure 2.

Figure 2 compares the mRNA expression levels of MDC (a) and TARC (b) in HaCaT cells induced with IFN-γ and TNF-α cytokines, according to the treatment of 70 wt% ethanol extract of the striatum prepared in Example 1. it is a graph Referring to FIG. 2, the mRNA expression levels of MDC and TARC showed similar trends, and it was confirmed that the mRNA expression levels were significantly decreased even at the lowest concentration of 10 μg/ml. In addition, it was found that the mRNA expression levels of MDC and TARC decreased in a concentration-dependent manner after a concentration of 10 μg/ml.

Figure 3 compares the protein expression levels of MDC (a) and TARC (b) in HaCaT cells induced with IFN-γ and TNF-α cytokines, according to the treatment of 70 wt% ethanol extract of the striatum prepared in Example 1. it is a graph Referring to FIG. 3, both TARC and MDC protein expression levels showed similar trends, and compared to the control group, IFN-γ and TNF-α two cytokines were treated. In the group, TARC and MDC expression levels were significantly increased. In the case of the MDC (a), it was confirmed that the protein expression level was inhibited in a concentration-dependent manner from the lowest concentration of 50 μg/ml. In addition, in the case of the TARC (b), the protein expression level was inhibited in a concentration-dependent manner from a concentration of 10 μg/ml.

Through this, it was found that the streptococcus extract prepared in Example 1 was very effective in inhibiting atopic dermatitis or allergic dermatitis by inhibiting the expression of TARC and MDC from IFN-γ and TNF-α cytokines in HaCaT cells. .

Experimental Example 3: Analysis of inflammatory pathways in atopy-related HaCaT cells

In order to confirm the signal transduction pathway mechanism (MAPKs pathway), which is an inflammatory pathway in HaCaT cells, by using a 70% by weight ethanol extract of the worm prepared in Example 1, it was measured using Western Blot. The measurement method was carried out by first isolating and quantifying proteins in cells, passing SDS-PAGE, and detecting only the target protein with a primary antibody and a secondary antibody. At this time, GAPDH, JNK, pJNK, p38, p-p38, (W)STAT1 and (W)pSTAT1 were used as HaCaT cells induced with IFN-γ and TNF-α cytokines, and the results are shown in FIG. 4 .

FIG. 4 shows the MAPKs and SAAT1 passages of HaCaT cells induced with IFN-γ and TNF-α cytokines in the striatum prepared in Example 1 after treatment with 70 wt% ethanol extract. Referring to FIG. 4, it was confirmed that the JNK and p38 phosphorylated signaling of the MAPKs pathway, known as an inflammation-related pathway, and STAT1 translocated into the nucleus were down-regulated by the stratus extract in a concentration-dependent manner. It was found that the composition containing 70% by weight ethanol extract of worms exhibited an anti-inflammatory effect on atopic dermatitis by regulating the CREB pathway.

Experimental Example 4: HPLC Analysis of Spinach Extract

The 70 wt% ethanol extract of the worm prepared in Example 1 was analyzed using HPLC to confirm the marker component, and the results are shown in FIG. 5.

5 shows the results of HPLC analysis of the 70% by weight ethanol extract of the worm prepared in Example 1. Referring to FIG. 5, it was confirmed that aldehyde-based components were detected as a result of analyzing the effective peaks in the 70% by weight ethanol extract of the worm.

Claims (18)

It contains Sargassum thunbergii extract extracted with 60 to 80% by weight of ethanol as an active ingredient,
The snailworm extract contains an aldehyde-based compound as an active ingredient and prevents atopic dermatitis or allergic dermatitis induced by the expression of MDC or TARC, which is included in a concentration of 50 to 100 μg/ml with respect to the total content of the cosmetic composition. Or a cosmetic composition for improvement.
delete delete According to claim 1,
The locust extract is a cosmetic composition for preventing or improving atopic dermatitis or allergic dermatitis induced by the expression of MDC or TARC, which is contained in a concentration of 100 μg / ml relative to the total content of the cosmetic composition.
delete According to claim 1,
The cosmetic composition is a suspension, emulsion, paste, gel, cream, atopic soap, cleansing foam, cleansing cream, cleansing water, bath agent, skin softener, skin toner, lotion, cream, essence, astringent, emulsion, gel, lipstick, By expression of MDC or TARC, which is any one formulation selected from the group consisting of spray, shampoo, rinse, treatment, body cleanser, pack, massage, face powder, compact, foundation, two-way cake and makeup base A cosmetic composition for preventing or improving induced atopic dermatitis or allergic dermatitis.
delete It contains Sargassum thunbergii extract extracted with 60 to 80% by weight of ethanol as an active ingredient,
The streptococcus extract contains an aldehyde-based compound as an active ingredient and is included in a concentration of 50 to 100 μg/ml based on the total content of the pharmaceutical composition, for atopic dermatitis or allergic dermatitis induced by expression of MDC or TARC A pharmaceutical composition for prevention or treatment.
delete According to claim 8,
The pharmaceutical composition is for preventing or treating atopic dermatitis or allergic dermatitis induced by the expression of MDC or TARC, further comprising at least one selected from the group consisting of a pharmaceutically acceptable carrier, excipient and diluent. pharmaceutical composition.
According to claim 8,
The pharmaceutical composition is any one formulation selected from the group consisting of granules, powders, tablets, coatings, capsules, solutions, syrups, juices, suspensions, emulsions, drops and injection solutions, MDC or TARC A pharmaceutical composition for the prevention or treatment of atopic dermatitis or allergic dermatitis induced by the expression of.
It contains Sargassum thunbergii extract extracted with 60 to 80% by weight of ethanol as an active ingredient,
The locust worm extract contains an aldehyde-based compound as an active ingredient and is included in a concentration of 50 to 100 μg/ml based on the total content of the composition for external application for skin, for atopic dermatitis or allergic dermatitis induced by the expression of MDC or TARC A composition for external application for skin for prevention or treatment.
delete According to claim 12,
The composition for external application for skin is any one formulation selected from the group consisting of creams, gels, ointments, emulsions, suspensions, sprays, and transdermal deliverable patches, atopic dermatitis or allergic dermatitis induced by the expression of MDC or TARC. A composition for external application for skin for the prevention or treatment of
It contains Sargassum thunbergii extract extracted with 60 to 80% by weight of ethanol as an active ingredient,
Prevention of atopic dermatitis or allergic dermatitis induced by the expression of MDC or TARC, wherein the streptococcus extract contains an aldehyde-based compound as an active ingredient and is included in a concentration of 50 to 100 μg/ml based on the total content of the quasi-drug composition Or a quasi-drug composition for improvement.
According to claim 15,
The quasi-drug composition is for preventing or improving atopic dermatitis or allergic dermatitis induced by the expression of MDC or TARC, which is any one formulation selected from the group consisting of disinfectant cleaners, shower foams, ointments, wet tissues and coating agents Quasi-drug composition.
It contains Sargassum thunbergii extract extracted with 60 to 80% by weight of ethanol as an active ingredient,
Atopic dermatitis or allergic dermatitis induced by the expression of MDC or TARC, wherein the streptococcus extract contains an aldehyde-based compound as an active ingredient and is included in a concentration of 50 to 100 μg/ml based on the total content of the health functional food composition. Health functional food composition for the prevention or improvement of.
According to claim 17,
The health functional food composition is any one formulation selected from the group consisting of capsules, tablets, powders, granules, liquids, pills, flakes, pastes, syrups, gels, jellies and bars, by the expression of MDC or TARC. Health functional food composition for preventing or improving induced atopic dermatitis or allergic dermatitis.

Images